Rallybio (NASDAQ:RLYB) Rating Lowered to “Sell” at Wall Street Zen

Rallybio (NASDAQ:RLYB) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a report on Wednesday. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Rallybio presently has a consensus rating of “Reduce” and a consensus price target of $5.00.

Rallybio Stock Down 7.7%

Rallybio stock opened at $0.51 on Friday. Rallybio has a twelve month low of $0.22 and a twelve month high of $1.24. The firm has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.44. The company has a market capitalization of $21.35 million, a P/E ratio of -0.54 and a beta of -1.10.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. The firm had revenue of $0.21 million during the quarter. Equities analysts expect that Rallybio will post -1.34 EPS for the current fiscal year.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.